EGFR and familial pancreatic carcinoma: Simultaneous treatment with gemcitabine and erlotinib was also investigated in pancreatic cancer (reviewed in [5]), where EGFR is over-expressed in more than 50% of cases [6–8], and gave a significant but limited improvement in overall survival of approximately two weeks, so this regimen has not been widely adopted, in consideration of its added toxicity [2].